Northwest Biotherapeutics (NWBO) Change in Accured Expenses (2010 - 2026)

Northwest Biotherapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $886000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 79.75% year-over-year to $886000.0 in Q1 2026; TTM through Mar 2026 was $4.3 million, a 51.45% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 13.26% from the prior year.
• Change in Accured Expenses grew to $886000.0 in Q1 2026 per NWBO's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.5 million in Q1 2024 and bottomed at -$2.6 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is $886000.0 (2026), against an average of $1.2 million.
• Across the five-year window, Change in Accured Expenses surged 640.58% in 2024 and sank 374.38% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.2 million in 2022, then slumped by 216.33% to -$2.6 million in 2023, then jumped by 115.42% to $402000.0 in 2024, then sank by 374.38% to -$1.1 million in 2025, then surged by 180.33% to $886000.0 in 2026.
• Per Business Quant, the three latest NWBO Change in Accured Expenses figures stand at $886000.0 (Q1 2026), -$1.1 million (Q4 2025), and $1.3 million (Q3 2025).